Compare Banco Santander SA (SAN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs BIO-TECHNE Corp — how do they compare? Banco Santander SA trades at $13.45 (market cap $192.86B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: Banco Santander SA is far larger — about 17× BIO-TECHNE Corp's market cap, and Banco Santander SA pays the higher dividend (2.06%). Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and BIO-TECHNE Corp for 64 Days on average.
| SAN | TECH | |
|---|---|---|
Market Cap | $192.86B | $11.36B |
Volume | 10,644,519 | 5,390,331 |
Sector | Financials | Health |
52-Week High | $15.05 | $72.61 |
52-Week Low | $9.65 | $43.31 |
Typical Hold Time | 55 Days | 64 Days |
Enterprise Value | $360.86B | $11.39B |
Dividend Yield | 2.06% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.44, down 1.65% today amid bearish technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q2 missing. Fundamentals remain solid with 26.25% net income margin and 16.07% ROE, though cash flow trends show recent weakness. Recent developments include the completed Webster acquisition expanding U.S. presence and record Q2 2026 profits driven by digital transformation.
SAN presents a value opportunity with reasonable P/E of 13.55 and strong analyst support (64% buy ratings), but faces risks from declining operating cash flows and high debt levels. The technical bearish signal suggests near-term pressure, while fundamental strength supports long-term potential for patient investors.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
